Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 10x Genomics, Inc.TXG · Entity 2172 | Director | June 11, 2024 | June 13, 2024 |
| JOHNSON & JOHNSONJNJ · Entity 2722 | EVP, Pharm, R&D | February 14, 2022 | February 17, 2022 |
| Parabilis Medicines, Inc.PBLS · Entity 3933 | Director · President & CEO | June 09, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
10x Genomics, Inc.
Report date June 11, 2024 · Filed June 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 180,259 |
Reported balance
After 2024-06-11 transaction · row 1
1 source rowRow 1 · 2024-06-11 · Grant · Acquired 8,649 · Balance 180,259 F1: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2024, subject to the Reporting Person continuing as a service provider through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2024, subject to the Reporting Person continuing as a service provider through each such date.
JOHNSON & JOHNSON
Report date February 14, 2022 · Filed February 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,934 |
Ending reported balance
After 2022-02-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-02-15 · Exercise / conversion · Acquired 7,740 · Balance 45,300 F1: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 11, 2019; converted into shares of Common Stock upon vesting. Row 2 · 2022-02-15 · Tax withholding · Disposed 3,366 · Balance 41,934 F2: Shares withheld for payment of taxes upon vesting of Performance Share Units. |
| Employee Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Expires 2032-02-14 | Direct | 38,736 |
Reported balance
After 2022-02-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-02-14 · Grant · Acquired 38,736 · Balance 38,736 F3: Awarded under Issuer's Long-Term Incentive Plan. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 3,922 |
Reported balance
After 2022-02-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-02-14 · Grant · Acquired 3,922 · Balance 3,922 F4: Awarded under Issuer's Long-Term Incentive Plan. Each Restricted Share Unit represents a contingent right to receive one share of Common Stock and vests three years after date of grant. |
| Performance Share UnitsSEC Table II · derivative / convertible security | Direct | 737 |
Reported balance
After 2022-02-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-02-15 · Exercise / conversion · Disposed 7,740 · Balance 737 F5: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 11, 2019. A portion of these Performance Share Units have been forfeited. |
Filing footnotes · ownership attribution and instrument terms
F1: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 11, 2019; converted into shares of Common Stock upon vesting.
F2: Shares withheld for payment of taxes upon vesting of Performance Share Units.
F3: Awarded under Issuer's Long-Term Incentive Plan.
F4: Awarded under Issuer's Long-Term Incentive Plan. Each Restricted Share Unit represents a contingent right to receive one share of Common Stock and vests three years after date of grant.
F5: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 11, 2019. A portion of these Performance Share Units have been forfeited.
Parabilis Medicines, Inc.
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.43 · Expires 2033-04-20 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-06-09 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: 25% of the shares subject to this option vested and became exercisable on March 16, 2024 with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.48 · Expires 2034-03-27 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-06-09 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from March 28, 2024, subject to the Reporting Person's continued service on each such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.48 · Expires 2034-03-27 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-06-09 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from March 28, 2024 contingent upon the achievement of certain performance objectives, subject to the Reporting Person's continued service on each such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.14 · Expires 2036-02-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-06-09 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from February 24, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to this option vested and became exercisable on March 16, 2024 with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F2: The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from March 28, 2024, subject to the Reporting Person's continued service on each such vesting date.
F3: The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from March 28, 2024 contingent upon the achievement of certain performance objectives, subject to the Reporting Person's continued service on each such vesting date.
F4: The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from February 24, 2026, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2024 Filed Jun 13, 2024 20:22 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 8,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000326 · form4.xml · nonDerivative · entry 1 Mammen Mathai · CIK 0001421050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,259 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2024, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:40 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 4,661 | $0.00 Strike: $57.62 | $0.00 |
DisclosureSEC source: 0001610717-23-000173 · form4.xml · derivative · entry 2 Mammen Mathai · CIK 0001421050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,661 Underlying: Class A Common Stock · 4,661 shares Expires 2033-06-14 F2 · derivative.exercise_date: 1/12th of the total number of shares subject to the option vest on each monthly anniversary measured from June 14, 2023, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:40 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 1,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000173 · form4.xml · nonDerivative · entry 1 Mammen Mathai · CIK 0001421050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,610 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2023, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| May 11, 2023 Filed May 15, 2023 20:37 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001610717-23-000035 · form4.xml · derivative · entry 3 Mammen Mathai · CIK 0001421050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 200,000 shares Expires 2027-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| May 11, 2023 Filed May 15, 2023 20:37 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 33,000 | $52.82 | $1,743,086.40 |
DisclosureSEC source: 0001610717-23-000035 · form4.xml · nonDerivative · entry 2 Mammen Mathai · CIK 0001421050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,745 F1 · price: This transaction was executed in multiple trades at prices ranging from $52.43 to $53.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 11, 2023 Filed May 15, 2023 20:37 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 200,000 | $1.16 | $232,000.00 |
DisclosureSEC source: 0001610717-23-000035 · form4.xml · nonDerivative · entry 1 Mammen Mathai · CIK 0001421050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 21:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 5,300 | $0.00 Strike: $39.62 | $0.00 |
DisclosureSEC source: 0001567619-22-013119 · doc1.xml · derivative · entry 2 Mammen Mathai · CIK 0001421050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,300 Underlying: Class A Common Stock · 5,300 shares Expires 2031-06-15 F2 · derivative.exercise_date: This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one-twelfth of the shares on July 15, 2022 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 21:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 2,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-013119 · doc1.xml · nonDerivative · entry 1 Mammen Mathai · CIK 0001421050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,745 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock. One-fourth of the RSUs, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, shall vest on August 21, 2022 and on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 11:00 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionPerformance Share Units · Derivative | 7,740 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002372 · doc4.xml · derivative · entry 5 Mammen Mathai · CIK 0001421050 · EVP, Pharm, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 737 Underlying: Common Stock · 7,740 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 11, 2019. A portion of these Performance Share Units have been forfeited. F5 · derivative.expiration_date: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 11, 2019. A portion of these Performance Share Units have been forfeited. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 11:00 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 3,366 | $165.89 | $558,385.74 |
DisclosureSEC source: 0001225208-22-002372 · doc4.xml · nonDerivative · entry 2 Mammen Mathai · CIK 0001421050 · EVP, Pharm, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,934 F2 · shares: Shares withheld for payment of taxes upon vesting of Performance Share Units. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 11:00 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 7,740 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002372 · doc4.xml · nonDerivative · entry 1 Mammen Mathai · CIK 0001421050 · EVP, Pharm, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 11, 2019; converted into shares of Common Stock upon vesting. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 01:03 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionRestricted Share Units · Derivative | 7,418 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002220 · doc4.xml · derivative · entry 3 Mammen Mathai · CIK 0001421050 · EVP, Pharm, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,418 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 11, 2019; converted into shares of Common Stock upon vesting. F1 · derivative.expiration_date: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 11, 2019; converted into shares of Common Stock upon vesting. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 01:03 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 2,335 | $168.85 | $394,264.75 |
DisclosureSEC source: 0001225208-22-002220 · doc4.xml · nonDerivative · entry 2 Mammen Mathai · CIK 0001421050 · EVP, Pharm, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,560 F2 · shares: Shares withheld for payment of taxes upon vesting of Restricted Share Units. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 01:03 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 7,418 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002220 · doc4.xml · nonDerivative · entry 1 Mammen Mathai · CIK 0001421050 · EVP, Pharm, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 11, 2019; converted into shares of Common Stock upon vesting. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 11:00 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantRestricted Share Units · Derivative | 3,922 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002372 · doc4.xml · derivative · entry 4 Mammen Mathai · CIK 0001421050 · EVP, Pharm, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,922 Underlying: Common Stock · 3,922 shares Expires not disclosed F4 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. Each Restricted Share Unit represents a contingent right to receive one share of Common Stock and vests three years after date of grant. F4 · derivative.expiration_date: Awarded under Issuer's Long-Term Incentive Plan. Each Restricted Share Unit represents a contingent right to receive one share of Common Stock and vests three years after date of grant. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 11:00 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantEmployee Stock Options (Right to Buy) · Derivative | 38,736 | $165.89 | $6,425,915.04 |
DisclosureSEC source: 0001225208-22-002372 · doc4.xml · derivative · entry 3 Mammen Mathai · CIK 0001421050 · EVP, Pharm, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,736 Underlying: Common Stock · 38,736 shares Expires 2032-02-14 F3 · security: Awarded under Issuer's Long-Term Incentive Plan. F3 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 21:50 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 1,563 | $0.00 Strike: $193.51 | $0.00 |
DisclosureSEC source: 0001209191-21-040689 · doc4.xml · derivative · entry 2 Mammen Mathai · CIK 0001421050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,563 Underlying: Class A Common Stock · 1,563 shares Expires 2031-06-11 F2 · derivative.exercise_date: This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one-twelfth of the shares on July 11, 2021 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 21:50 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040689 · doc4.xml · nonDerivative · entry 1 Mammen Mathai · CIK 0001421050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock. One-fourth of the RSUs, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, shall vest on August 21, 2021 and on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:29 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 4,432 | $0.00 Strike: $88.42 | $0.00 |
DisclosureSEC source: 0001209191-20-037270 · doc4.xml · derivative · entry 1 Mammen Mathai · CIK 0001421050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,432 Underlying: Class A Common Stock · 4,432 shares Expires 2030-06-15 F1 · derivative.exercise_date: This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one-twelfth of the shares on July 15, 2020 and each month thereafter, subject to the reporting person continuing as a service provider through each such date. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 20:19 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0000899243-19-023636 · doc4.xml · derivative · entry 2 Mammen Mathai · CIK 0001421050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Class A Common Stock · 200,000 shares Expires 2027-06-12 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. F2 · derivative.exercise_date: One forty-eighth of the shares subject to the option vested on July 12, 2017 and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. This option may be exercised prior to vesting, subject to the Issuer's right to repurchase unvested shares. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 20:19 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0000899243-19-023636 · doc4.xml · derivative · entry 1 Mammen Mathai · CIK 0001421050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 200,000 shares Expires 2027-06-12 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. F2 · derivative.exercise_date: One forty-eighth of the shares subject to the option vested on July 12, 2017 and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. This option may be exercised prior to vesting, subject to the Issuer's right to repurchase unvested shares. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.